281 related articles for article (PubMed ID: 33336398)
1. Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
Huang RSP; Haberberger J; Sokol E; Schrock AB; Danziger N; Madison R; Trabucco S; Jin D; Pavlick D; Ramanan V; Hole K; McGregor K; Venstrom J; Ross JS
Int J Cancer; 2021 Apr; 148(7):1778-1788. PubMed ID: 33336398
[TBL] [Abstract][Full Text] [Related]
2. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract][Full Text] [Related]
4. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
5. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract][Full Text] [Related]
6. ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer.
Cai L; Duan J; Qian L; Wang Z; Wang S; Li S; Wang C; Zhao J; Zhang X; Bai H; Wang J
Front Immunol; 2020; 11():527750. PubMed ID: 33324391
[TBL] [Abstract][Full Text] [Related]
7. ROS1 [corrected].
Pal P; Khan Z
J Clin Pathol; 2017 Dec; 70(12):1001-1009. PubMed ID: 28903995
[TBL] [Abstract][Full Text] [Related]
8. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Cui M; Han Y; Li P; Zhang J; Ou Q; Tong X; Zhao R; Dong N; Wu X; Li W; Jiang G
Mol Oncol; 2020 Nov; 14(11):2787-2795. PubMed ID: 32871626
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
[TBL] [Abstract][Full Text] [Related]
10. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
[TBL] [Abstract][Full Text] [Related]
11. Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
Nagasaka M; Zhang SS; Baca Y; Xiu J; Nieva J; Vanderwalde A; Swensen JJ; Spetzler D; Korn WM; Raez LE; Liu SV; Ou SI
BMC Cancer; 2023 Oct; 23(1):1000. PubMed ID: 37853341
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.
Park E; Choi YL; Ahn MJ; Han J
Pathol Res Pract; 2019 Jul; 215(7):152441. PubMed ID: 31085007
[TBL] [Abstract][Full Text] [Related]
13. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
14. TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.
Zhu VW; Upadhyay D; Schrock AB; Gowen K; Ali SM; Ou SH
Lung Cancer; 2016 Jul; 97():48-50. PubMed ID: 27237027
[TBL] [Abstract][Full Text] [Related]
15. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
16. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
[TBL] [Abstract][Full Text] [Related]
17. Identification of
Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
[TBL] [Abstract][Full Text] [Related]
18. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.
Li W; Fei K; Guo L; Wang Y; Shu C; Wang J; Ying J
J Thorac Oncol; 2024 Apr; 19(4):613-625. PubMed ID: 38070598
[TBL] [Abstract][Full Text] [Related]
19. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
20. ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.
Liu Z; Zhao K; Wei S; Liu C; Zhou J; Gou Q; Wu X; Yang Z; Yang Y; Peng Y; Cheng Q; Liu L
Oncoimmunology; 2020 May; 9(1):1758003. PubMed ID: 32923114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
